Adaptimmune, MSD to test multiple myeloma combo
Oxford, UK-based Adaptimmune has formed a clinical trial pact with MSD to test a potential new combination therapy for multiple myeloma.
Read More
Tag: NY-ESO SPEAR
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
